Pharmaceuticals
China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation
SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) ofChina has accepted the...
2023-11-24 19:00
2268
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of early iron deficiency diagnosis and treatment and its impact on quality of life ST. GALLEN, SWITZERL...
2023-11-24 15:00
4040
Everest Medicines Announces China NMPA's Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patients-- SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the ...
2023-11-24 12:54
4051
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-11-24 08:42
4228
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL...
2023-11-23 16:04
4574
PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome
* Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease) and vessel-related rare disease indications * Unique Tie2-activating antibody program, PMC-403, demonstrates efficacy in improving survival and reducing vascular leak...
2023-11-23 10:31
1686
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-11-23 08:00
3470
Ark Biopharmaceutical Receives IND Approval from NMPA for AK0610, a Respiratory Syncytial Virus Neutralizing Antibody
SHANGHAI, Nov. 23, 2023 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announces that it had received IND approval from National Medical Products Administration (NMPA) for a novel antibody drug AK0610. This antibody drug is bioengineered based on a neutralizing antibody origina...
2023-11-23 08:00
2692
CMI Inc. and Life Molecular Imaging Announce the Reimbursement of the Amyloid-PET Diagnostic Neuraceq® (florbetaben 18F) in Japan
First Reimbursed Amyloid PET Diagnostic Tool in Japan TOKYO and BERLIN, Nov. 23, 2023 /PRNewswire/ -- CMI Inc. and Life Molecular Imaging (LMI) are pleased to announce that the amyloid-PET diagnostic Neuraceq® (florbetaben18F injection) has been approved from the Ministry of Health, Labor, and ...
2023-11-23 01:00
1952
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale * This end-to-end continuous bioprocess, which is in place for WuXi Biologics global manufacturing network, is...
2023-11-22 13:21
3676
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
ROCKVILLE, Md.and SUZHOU,China, Nov. 22, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ot...
2023-11-22 12:40
6325
XtalPi and EDDC Sign New Collaboration, Empowering Biomedical Innovation with Robotics and Large Language Models
SHENZHEN, China, Nov. 22, 2023 /PRNewswire/ -- Today, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC),Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboratio...
2023-11-22 09:00
2484
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition
- Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients - ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors...
2023-11-21 20:15
2143
ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop
SEOUL, South Korea, Nov. 20, 2023 /PRNewswire/ -- Nov. 21, 2023 local time, ST Pharm announced 'Rapid Preparedness of Pandemic Vaccine in 100 Days using ST Pharm's own mRNA Platform Technology' at the Korea-CEPI R&D Workshop in World Bio Summit 2023, organized by Korea Health Industry Development...
2023-11-21 12:00
1492
Porton Advanced and Ascle Therapeutics Reached a Strategic Partnership to Promote the Application of NK Cells in Cancer Prevention, Beauty, and Anti-aging
SUZHOU, China, Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Porton Advanced announced a strategic partnership with Ascle Therapeutics to jointly develop and produce NK cells, assist in the development and innovation in gene and cell therapy, and accelerate the application of NK cells in ca...
2023-11-20 20:00
1284
First Subject Enrolled in Phase 1 Study of MRX-5
SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as ＂MicuRx＂) announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...
2023-11-20 18:34
1507
Sanyou's "STAL Platform" is a significant advancement in the field of drug discovery.
SHANGHAI, Nov. 17, 2023 /PRNewswire/ -- Sanyou's "STAL Innovative Biologics Drug Discovery Platform" is a significant advancement in the field of drug discovery. This cutting-edge platform enables the screening of thousands of innovative lead molecules against a common target, surpassing the capa...
2023-11-18 08:00
3127
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
Conference call webcast is scheduled for November 22 at 9 a.m. ET.
SINGAPORE, Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-11-17 22:21
3836
Taiwan Lubricate for academic research and health products development
TAICHUNG, Nov. 17, 2023 /PRNewswire/ -- Based in Taiwan, T-BAL is the leading service provider in measurements of lipids and metabolites for both academics and industry. In the collaboration with Lipotype GmbH,Germany (the world leader in lipidomics profiling service), T-BAL has developed advance...
2023-11-17 20:00
1281
epitoMAP Inc., Animal Allergy Clinical Laboratories Inc. and Nippon Zenyaku Kogyo Co., Ltd. Enter into License Agreement
SAGAMIHARA, Japan, Nov. 17, 2023 /PRNewswire/ -- epitoMAP Inc. (hereinafter "epitoMAP") and Animal Allergy Clinical Laboratories Inc. (hereinafter "AACL") entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. (hereinafter...
2023-11-17 16:00
1445
Week's Top Stories
Most Reposted
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00
Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 293 media titles]
2025-01-23 09:00
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 291 media titles]
2025-01-28 10:49
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Dahua Technology Joins Hands with WWF to Expand Sustainability Efforts Globally
[Picked up by 270 media titles]
2025-01-24 12:15
Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
7665
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5438